2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 359

The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk
Abstract Number: 2360

The Association of Superolateral Hoffa’s Fat Pad Edema and Synovitis with Structural Changes in the Patellofemoral and Tibiofemoral Joints: The Multicenter Osteoarthritis Study
Abstract Number: 2929

The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis
Abstract Number: 1L

The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
Abstract Number: 3143

The Caspase 8/RIPK3 Signaling Axis in Dendritic Cells Controls Joint Homeostasis Under Steady-State and Arthritic Conditions
Abstract Number: 2883

The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway
Abstract Number: 3079

The Characteristic Features of the Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Abstract Number: 3004

The Choosing Wisely Initiative: Is It Complete?
Abstract Number: 314

The Clinical Efficacy and Safety of the Gumiganhwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study
Abstract Number: 2918

The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Abstract Number: 607

The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)
Abstract Number: 2322

The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle
Abstract Number: 2366

The Clinical Utility of the Bulge Sign in Evaluating Knee Osteoarthritis
Abstract Number: 2723

The Co-Occurrence of Axial Spondyloarthritis and Fibromyalgia: A National Register-Based Study
Abstract Number: 1581

The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].